SCHEMBL1804347

SCHEMBL1804347

NC(=O)c1cc(F)ccc1I

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.47
CES2 O00748 3/20 0.47
CES1 P23141 3/20 0.47
PARP1 P09874 3/20 0.44
DGAT1 O75907 1/20 0.41
CDC7 O00311 1/20 0.40
IKBKB O14920 2/20 0.38
MEN1 O00255 1/20 0.38
JAK2 O60674 1/20 0.38
EIF2AK2 P19525 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TTR P02766 1/20 0.38
MAPK8 P45983 2/20 0.37
ANO1 Q5XXA6 1/20 0.36
KCNN4 O15554 1/20 0.36
MAP2K2 P36507 1/20 0.36
MAP2K1 Q02750 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24006621 0.83 CES2 (0.47) KEAP1CES2CES1PARP1DGAT1
SCHEMBL27883282 0.83 CES2 (0.50) KEAP1CES2CES1TTRANO1
SCHEMBL1150930 0.81 KEAP1 (0.59) KEAP1CES2CES1MEN1KMT2A
SCHEMBL30762574 0.81 KEAP1 (0.59) KEAP1CES2CES1MEN1KMT2A
SCHEMBL29463969 0.80 CES2 (0.52) KEAP1CES2CES1PARP1DGAT1
SCHEMBL2584947 0.79 CES2 (0.47) KEAP1CES2CES1KMT2ATTR
SCHEMBL31448305 0.79 CES2 (0.47) KEAP1CES2CES1KMT2ATTR
SCHEMBL28423060 0.79 CES2 (0.47) KEAP1CES2CES1TTRANO1
SCHEMBL31373249 0.78 MAP2K2 (0.41) PARP1DGAT1IKBKBMEN1KMT2A
SCHEMBL29537903 0.78 CES2 (0.68) KEAP1CES2CES1PARP1DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3429994-B1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LTD (GB) 2021-06-16 EP disclosed
CN-105294597-B Benzothiazine derivatives and its synthetic method and application 华东师范大学 2017-11-24 CN disclosed
WO-2017158388-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LIMITED (GB) 2017-09-21 WO disclosed
CN-105294597-A Benzothiazine derivative, and synthetic method and application thereof UNIV EAST CHINA NORMAL 2016-02-03 CN disclosed
EP-2493303-A1 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS Merck Sharp & Dohme Corp. (US) 2012-09-05 EP disclosed
US-20120214847-A1 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS MERCK SHARP & DOHME CORP. (US) 2012-08-23 US disclosed
US-20120214847-A1 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS MERCK SHARP & DOHME CORP. (US) 2012-08-23 US disclosed
WO-2011053574-A1 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS MERCK SHARP & DOHME CORP. (US) 2011-05-05 WO disclosed
WO-2011053574-A1 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS MERCK SHARP & DOHME CORP. (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214847-A1 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS NR3C1, NR3C2, NR5A1 KEAP1 1928/4885CES2 4577/4885CES1 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.